Clovis Oncology (CLVS) Tops Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as higher oil prices temper risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
Clovis Oncology Announces Third Quarter 2020 Operating Results
November 5, 2020 8:05 AM EST$38.8M in Rubraca® (rucaparib) global sales for Q3 2020; net product revenue up 3% over Q3 2019 Global net product revenue guidance provided for Q4 2020 in a range of $38M to $40M Restructuring U.S. commercial organization to adopt hybrid strategy elevating digital programming and peer-to-peer interactions Oncology pipeline, inclusive of Rubraca, lucitanib and FAP-2286, expected to result in multiple key clinical, development and regulatory milestones during 2021 $224.7M in cash and cash equivalents at September 30, 2020, which is anticipated to fund the Companys operating plan into early... More
